D. Boral Capital Reaffirms Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $34.00 price objective on the stock.

Several other research firms have also issued reports on NRXP. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. HC Wainwright increased their target price on NRx Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Ascendiant Capital Markets restated a “buy” rating and set a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Finally, BTIG Research reissued a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.00.

NRx Pharmaceuticals Stock Performance

NRXP opened at $2.55 on Monday. The stock has a market capitalization of $84.33 million, a P/E ratio of -1.83 and a beta of 1.83. The stock has a 50-day moving average price of $2.01 and a 200-day moving average price of $2.35. NRx Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Monday, March 23rd. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.28. The business had revenue of $0.98 million for the quarter, compared to the consensus estimate of $7.53 million. On average, equities research analysts predict that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NRXP. One Wealth Management Investment & Advisory Services LLC raised its position in shares of NRx Pharmaceuticals by 35.3% in the 4th quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock worth $103,000 after acquiring an additional 9,882 shares in the last quarter. State Street Corp boosted its position in shares of NRx Pharmaceuticals by 14.0% in the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after purchasing an additional 10,700 shares in the last quarter. Ethos Financial Group LLC bought a new position in shares of NRx Pharmaceuticals during the third quarter valued at $39,000. Sjbenen Advisory LLC purchased a new stake in NRx Pharmaceuticals during the 4th quarter valued at about $41,000. Finally, Two Sigma Investments LP raised its holdings in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.